<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03536754</url>
  </required_header>
  <id_info>
    <org_study_id>CL011_140</org_study_id>
    <secondary_id>LUMINA-1</secondary_id>
    <nct_id>NCT03536754</nct_id>
  </id_info>
  <brief_title>A Study of CCX140-B in Subjects With FSGS</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Focal Segmental Glomerulosclerosis (FSGS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ChemoCentryx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medpace, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ChemoCentryx</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate&#xD;
      the Safety and Efficacy of CCX140-B in Subjects with FSGS to be conducted in the North&#xD;
      America, Europe and Australia&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate&#xD;
      the Safety and Efficacy of CCX140-B in Subjects with Focal Segmental Glomerulosclerosis&#xD;
      (FSGS) to be conducted in the North America, Europe and Australia. The aim of this study is&#xD;
      to evaluate the effect of treatment with CCX140-B, a selective antagonist of C-C chemokine&#xD;
      receptor type 2 in subjects with focal segmental glomerulosclerosis on urinary protein&#xD;
      excretion as assessed by changes in urine protein to creatinine ratio (UPCR)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2018</start_date>
  <completion_date type="Actual">February 19, 2020</completion_date>
  <primary_completion_date type="Actual">November 26, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Randomized, placebo-controlled, Phase 2</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Changes from baseline in urine protein to creatinine ratio (UPCR)</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>Effect of CCX140-B on treatment of urinary protein excretion in subjects with FSGS as assessed by changes from baseline in UPCR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in renal function as assessed by changes in eGFR using several equations (see description)</measure>
    <time_frame>Baseline to weeks 12 and 24</time_frame>
    <description>Effect of CCX140-B on renal function as assessed by eGFR using the CKD-EPI Cystatin C, CKD-EPI creatinine equation, CKD-EPI creatinine-cystatin c equation and NDRD creatinine equation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in PK profile as measured by Auc0-6 at steady state at intervals throughout the treatment period</measure>
    <time_frame>Baseline to weeks 12 and 24</time_frame>
    <description>Effect of CCX140-B on the PK profile in subjects with FSGS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in PK profile as measured by Cmin at intervals throughout the treatment period</measure>
    <time_frame>Baseline to weeks 12 and 24</time_frame>
    <description>Evaluation of the PK profile of CCX140-B in subjects with FSGS</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>FSGS</condition>
  <condition>Focal Segmental Glomerulosclerosis</condition>
  <condition>Glomerulosclerosis</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (N=10)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CCX140-B 5 mg once daily (N=10)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CCX140-B 10 mg twice daily (N=10)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CCX140-B 15 mg twice daily (N=10)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Group A</arm_group_label>
    <other_name>CCX140-B Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CCX140-B</intervention_name>
    <description>CCX140-B is an orally administered selective antagonist of CCR2</description>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female subjects aged 18-75&#xD;
&#xD;
          2. UPCR ≥ 1 g protein/g creatinine (or at 113 mg.mmol) at screening&#xD;
&#xD;
          3. Diagnosis of FSGS based on renal biopsy or high risk genetic variant&#xD;
&#xD;
          4. Diagnosis of one of primary FSGS based on characteristic histopathology, medical&#xD;
             history and clinical course or FSGS secondary to genetic variants associated with&#xD;
             increased risk or severity.&#xD;
&#xD;
          5. Estimated glomerular filtration rate (eGFR) &gt;30 mL/min/1.73m2&#xD;
&#xD;
          6. Clinical stable blood pressure not to exceed 145/95 mmHg&#xD;
&#xD;
          7. RAAS blockers must be stable for at least 4 weeks prior to screening and projected to&#xD;
             remain stable through week 12, unless adjustments are required for management of&#xD;
             hypertension.&#xD;
&#xD;
          8. Immunosuppressive or immunomodulatory therapy must be stable for at least 4 weeks&#xD;
             prior to screening and projected to remain stable through study week 12&#xD;
&#xD;
          9. Glucocorticoids must be stable for at least 4 weeks prior to screening and projected&#xD;
             to remain stable through study week 12.&#xD;
&#xD;
         10. Both genders of childbearing potential must agree to use adequate contraception during&#xD;
             and for at least 3 months after the last dose of study drug.&#xD;
&#xD;
         11. Subjects must be willing and able to give written Informed Consent and to comply with&#xD;
             protocol requirements.&#xD;
&#xD;
         12. Subjects must be judged to be otherwise fit for the study by the Investigator. -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or nursing&#xD;
&#xD;
          2. History of organ transplantation&#xD;
&#xD;
          3. On an organ transplant waiting list or anticipated organ transplant within 6 months of&#xD;
             screening&#xD;
&#xD;
          4. Anti-CD20 monoclonal antibodies within 20 months of screening are exclusionary.&#xD;
             Subjects that used anti CD20 monoclonal antibodies prior to week 20 are allowed with&#xD;
             confirmed recovery of CD20+ B cell population to within normal range&#xD;
&#xD;
          5. Plasmapheresis within 12 weeks of screening&#xD;
&#xD;
          6. BMI ≥40&#xD;
&#xD;
          7. Participation in any clinical study of an investigational product within 12 weeks or 5&#xD;
             half-lives of screening&#xD;
&#xD;
          8. Currently on dialysis or likely to require dialysis during the blinded treatment phase&#xD;
             of the study.&#xD;
&#xD;
          9. History or presence of any form of cancer within 5 years of screening except excised&#xD;
             basal cell or squamous cell carcinoma or carcinoma in situ such as cervical or breast&#xD;
             carcinoma in situ that has been excised or completed resected without evidence or&#xD;
             recurrence.&#xD;
&#xD;
         10. Positive HBV, HCV, or HIV viral screening test. Subjects who have received highly&#xD;
             effective therapy for HCV demonstrated to have negative viral titers for at least 6&#xD;
             months following discontinuation of treatment, will be considered to have a negative&#xD;
             HCV screening test&#xD;
&#xD;
         11. Renal disease associated with disorders other than FSGS that is active or has&#xD;
             significant risk of progressing during the course of the study.&#xD;
&#xD;
         12. Disorders that are associated with FSGS lesions.&#xD;
&#xD;
         13. Evidence of tuberculosis.&#xD;
&#xD;
         14. Evidence of hepatic disease with the exception that isolated INR elevation in the&#xD;
             absence of other significant liver enzyme abnormalities is explained by anticoagulant&#xD;
             therapy, (e.g. warfarin)&#xD;
&#xD;
         15. Hematologic abnormalities as follows: Hb &lt;8 g/dL, platelets &lt;50,000, ANC &lt;1000&#xD;
             cells/µL) at baseline.&#xD;
&#xD;
         16. QTcF greater than 450 msec.&#xD;
&#xD;
         17. History of alcohol or illicit drug abuse or of lithium, pamidronate and interferon.&#xD;
             Recreational use of cannabis is not excluded where legal.&#xD;
&#xD;
         18. History of gastrointestinal conditions that may interfere with study medication&#xD;
             compliance.&#xD;
&#xD;
         19. Known hypersensitivity to CCX140-B or inactive ingredients of the CCX140-B tablets&#xD;
             (including microcrystalline cellulose, starch, crospovidone, magnesium stearate, or&#xD;
             silicon dioxide).&#xD;
&#xD;
         20. History or presence of systemic disorder other than FSGS that requires, or is expected&#xD;
             to require, systemic glucocorticoids or immune modulators during the study; topical or&#xD;
             inhaled glucocorticoids and immune modulators are not excluded.&#xD;
&#xD;
         21. History or presence of any medical condition or disease which, in the opinion of the&#xD;
             Investigator, may place the subject at unacceptable risk for study participation.&#xD;
&#xD;
         22. Subjects taking strong CYP3A4 inducers or strong CYP3A4 inhibitors within two weeks&#xD;
             prior to screening.&#xD;
&#xD;
         23. Subjects taking lithium or interferon; subjects taking non-steroidal anti-inflammatory&#xD;
             agents (NSAIDS) chronically (intermittent, i.e. occasional NSAIDS for pain or fever is&#xD;
             discouraged, but is not excluded).&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Staehr, MD</last_name>
    <role>Study Director</role>
    <affiliation>ChemoCentryx</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AKDHC</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Los Angeles Biomedical Research Institute</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Louisiana Nephrology</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MGH</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Carolina University</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Sciences Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Utah Kidney Research Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Health</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Parkville</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Josephs Healthcare - Hamilton</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre (Odette Cancer Center)</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4G 3E8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CISSS de la Monteregie-Centre - Hopital Charles LeMoyne</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V2H1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux- Hospital Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble cedex 9</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHM - Hopital de la Conception</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopitaux Prives de Metz</name>
      <address>
        <city>Metz</city>
        <zip>57045</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII</name>
      <address>
        <city>Bergamo</city>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Azienda Ospedaliera Universitaria San Martino IST</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presidio Ospedaliero di Montichiari-A.O. Spedali Civili di Brescia</name>
      <address>
        <city>Montichiari</city>
        <zip>25018</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione S. Maugeri IRCCS</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario A. Gemelli - Universita Cattolica del Sacro Cuore</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore Hospital</name>
      <address>
        <city>Takapuna</city>
        <state>Auckland</state>
        <zip>0622</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taranaki Base Hospital</name>
      <address>
        <city>New Plymouth</city>
        <zip>4310</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Kliniczny w Bialymstoku - II Klinika Nefrologii z Oddzialem Leczenia Nadcisnienia Tetniczego i Pododdzialem Dializoterapii</name>
      <address>
        <city>Białystok</city>
        <zip>15-276</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SCM Sp. Zo.o.</name>
      <address>
        <city>Kraków</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny</name>
      <address>
        <city>Szczecin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Kliniczny Klinika Nefrologii i Medycyny Transplantacyjnej</name>
      <address>
        <city>Wrocław</city>
        <zip>50-556</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Zaklad Opieki Zdrowotnez Centralny Szpital</name>
      <address>
        <city>Łódź</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cambridge University - Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0OQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Wales</name>
      <address>
        <city>Cardiff</city>
        <zip>CF14 4XW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Salford Royal NHS Foundation Trust Manchester</name>
      <address>
        <city>Salford</city>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morriston Hospital</name>
      <address>
        <city>Swansea</city>
        <zip>SA6 6NL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>France</country>
    <country>Italy</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 28, 2018</study_first_submitted>
  <study_first_submitted_qc>May 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 25, 2018</study_first_posted>
  <last_update_submitted>April 2, 2021</last_update_submitted>
  <last_update_submitted_qc>April 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glomerulosclerosis, Focal Segmental</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

